ROS1 and non-small cell lung carcinoma: Of note, Crizotinib was first approved for the treatment of ALK-rearranged NSCLC and ROS1-rearranged NSCLC, but then it has been demonstrated that it could be recruited in NSCLC with MET amplification [135].